Patent Application
20100063060
The present invention relates to a therapeutic agent for glaucoma comprising the combination of a Rho kinase inhibitor and a prostaglandin.
Glaucoma is an intractable ocular disease with a risk of blindness, involving the increase of intraocular pressure due to various factors and by disordering internal tissues of eyeballs (retina, an optic nerve and the like). A general method of treating glaucoma is intraocular pressure reduction therapy, which is exemplified by pharmacotherapy, laser therapy, surgery therapy and the like.
For pharmacotherapy, drugs such as sympathomimetic agents (nonselective stimulants such as epinephrine, a 2 stimulants such as apraclonidine), sympatholytic agents (β-blockers such as timolol and befunolol, α1-blockers such as bunazosin hydrochloride), parasympathomimetic agents (pilocarpine and the like), carbonic anhydrase inhibitors (acetazolamide and the like) and prostaglandins (isopropyl unoprostone, latanoprost, travoprost, bimatoprost and the like) have been used.
Recently, a Rho kinase inhibitor was found to serve as a therapeutic agent for glaucoma based on a new mechanism of action (WO 00/09162). Invest. Opthalmol. & Vis. Sci., 42 (1), 137-144 (2001) discloses that a Rho kinase inhibitor increases the aqueous humor outflow from a trabecular meshwork outflow pathway thereby reducing intraocular pressure. Invest. Opthalmol. & Vis. Sci., 42 (1), 137-144 (2001) and Invest. Opthalmol. & Vis. Sci., 42 (5), 1029-1037 (2001) suggest that the mechanism of action is reconstruction of cytoskeleton in trabecular meshwork cells.
Combined use of drugs having actions of reducing intraocular pressure to treat glaucoma has already been studied and there are some reports on the studies. For example, Japanese Patent No. 2726672 reports combined administration of the sympatholytic agent with prostaglandins. WO 02/38158 discloses a method of treating glaucoma by administering to eyes a combination of drugs having a capacity of reducing intraocular pressure.
However, such reports do not describe the Rho kinase inhibitor at all, and naturally, there is no description concerning advantageous effects brought about by combining the Rho kinase inhibitor with prostaglandins, either.
As mentioned above, there has been no study or report concerning the therapeutic effects on glaucoma obtained by combining a Rho kinase inhibitor with prostaglandins.
It was a very interesting finding of the present inventors to discover a therapeutic agent for glaucoma comprising a combination of a Rho kinase inhibitor and a prostaglandin.
Studying precisely the effects due to the combination of a Rho kinase inhibitor and a prostaglandin, the present inventors found that an action of reducing intraocular pressure is increased and/or the persistence of the action is improved by combining these drugs compared with a case where each drug is used alone, and consequently the present inventors completed the present invention. Detailed test methods and their effects are described hereinafter in the section entitled “Pharmacological Tests”. A remarkable increase in the action of reducing intraocular pressure and/or a remarkable improvement of the persistence of the action was observed by combining a Rho kinase inhibitor with a prostaglandin.
The present invention relates to a therapeutic agent for glaucoma comprising the combination of a Rho kinase inhibitor and a prostaglandin. These drugs each other complement and/or enhance their actions.
Regarding the mode of administration, each of the Rho kinase inhibitor and the prostaglandin can be in a separate preparation and these drugs can be administered in combination. Alternatively, these drugs can be formulated in a single preparation to be administered. In other words, these drugs can be administered in a mixture.
The Rho kinase inhibitors and prostaglandins used in the present invention include salts thereof. When these compounds have a basic group such as an amino group, they form salts with an inorganic acid such as hydrochloric acid or nitric acid or with an organic acid, such as oxalic acid, succinic acid or acetic acid. When they have an acidic group such as a carboxyl group, they form salts with an alkali metal such as sodium or potassium or with an alkaline earth metal such as calcium.
The Rho kinase inhibitors and prostaglandins used in the present invention include derivatives thereof such as esters. Specific examples of esters are alkyl esters such as methyl esters, ethyl esters and isopropyl esters.
The present invention is characterized by treating glaucoma with a combination of a Rho kinase inhibitor and a prostaglandin.
The Rho kinase inhibitor used in the present invention means a compound which inhibits serine/threonine kinase activated by the activation of Rho. Examples of Rho kinase inhibitors are compounds which inhibit ROKα (ROCK-II), p160ROCK (ROKβ, ROCK-I) and other compounds which inhibit proteins having a serine/threonine kinase activity. Specific Rho kinase inhibitors are exemplified by Rho kinase inhibitors such as (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide and (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)-benzamide disclosed in WO 98/06433 and WO 00/09162; Rho kinase inhibitors such as 145-isoquinolinesulfonyl)homopiperazine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine disclosed in WO 97/23222 and Nature, 389, 990-994 (1997); Rho kinase inhibitors such as (1-benzylpyrrolidin-3-yl)-(1H-indazol-5-yl)amine disclosed in WO 01/56988; Rho kinase inhibitors such as (1-benzylpiperidin-4-yl)-(1H-indazol-5-yl)amine disclosed in WO 02/100833; Rho kinase inhibitors such as N-[2-(4-fluorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N-(1H-indazol-5-yl)amine disclosed in WO 02/076976; Rho kinase inhibitors such as N-4-(1H-indazol-5-yl)-6,7-dimethoxy-N-2-pyridin-4-yl-quinazolin-2,4-diamine disclosed in WO 02/076977; and Rho kinase inhibitors such as 4-methyl-5-(2-methyl-[1,4]diazepan-1-sulfonyl)isoquinoline disclosed in WO 99/64011.
Any prostaglandin having the action of reducing intraocular pressure and which has utility in treating glaucoma can be used in the present invention. Prostaglandins having an action of reducing intraocular pressure are specifically exemplified by prostaglandins described in Japanese Laid-open Patent Publication No. 1418/1984 (natural prostaglandins, particularly prostaglandin F2α); prostaglandins such as latanoprost as described in Published Japanese Translation of PCT No. 501025/1991; prostaglandins such as isopropyl unoprostone as described in Japanese Laid-open Patent Publication No. 108/1990; prostaglandins such as bimatoprost as described in Published Japanese Translation of PCT No. 501310/1996; and prostaglandins such as travoprost as described in Japanese Laid-open Patent Publication No. 182465/1998. In particular, latanoprost, isopropyl unoprostone, bimatoprost and travoprost, which have already been on the market as a therapeutic agent of glaucoma, are preferred for use in the present invention.
Examples of glaucoma in the present invention are primary open angle glaucoma, normal intraocular tension glaucoma, hypersecretion glaucoma, ocular hypertension, acute angle-closure glaucoma, chronic closed angle glaucoma, combined-mechanism glaucoma, corticosteroid glaucoma, amyloid glaucoma, neovascular glaucoma, malignant glaucoma, capsular glaucoma, plateau iris syndrome and the like.
To carry out the present invention, preparations can be in the form of two preparations prepared by formulating a Rho kinase inhibitor and a prostaglandin separately or one preparation prepared by mixing these ingredients. Particular techniques are unnecessary for the formulation, and the preparations can be prepared using widely used techniques. A preferred method of administration is topical eye administration, and a preferred dosage form is an ophthalmic solution or an eye ointment.
When a Rho kinase inhibitor and a prostaglandin are formulated in preparations separately, each preparation can be prepared according to known methods. For example, the Rho kinase inhibitor can be formulated in preparations by referring to the Formulation Examples described in the above-mentioned International Publications (WO 00/09162 and WO 97/23222). Prostaglandins can be formulated in preparations by referring to the Formulation Examples described in the above-mentioned Japanese Laid-open Patent Publications and Published Japanese Translations of PCT (i.e. Japanese Laid-open Patent Publication No. 1418/1984, Published Japanese Translation of PCT No. 501025/1991, Japanese Laid-open Patent Publication No. 108/1990, Published Japanese Translation of PCT No. 501310/1996 and Japanese Laid-open Patent Publication No. 182465/1998), and particularly for latanoprost, isopropyl unoprostone, bimatoprost, travoprost and the like, which have already been on the market as therapeutic agents for glaucoma, commercially available preparations thereof can be used.
A formulation containing a Rho kinase inhibitor and a prostaglandin in a mixture also can be prepared according to known methods. The ophthalmic solutions can be prepared, using isotonic agents such as sodium chloride and concentrated glycerin; buffers such as sodium phosphate buffer and sodium acetate buffer; surfactants such as polyoxyethylene sorbitan monooleate, stearate polyoxyl 40, and polyoxyethylene hardened castor oil; stabilizers such as sodium citrate and sodium edetate; and preservatives such as benzalkonium chloride and paraben, as needed. The pH should be within an opthalmologically acceptable range and is preferably within a range of pH 4 to pH 8. For reference, a formulation example thereof is described below in the Example section. However, the formulation examples do not limit the scope of the invention.
The doses of Rho kinase inhibitor and prostaglandin can be determined depending on the symptoms and age of the patients, the dosage form, the administration route and the like. The case of instillation is briefly described below. The dose of the Rho kinase inhibitor varies depending on the drug type. The Rho kinase inhibitor can be administered generally within 0.025 to 10,000 mg daily from once to several times a day. The dose can be appropriately raised or lowered depending on the age and symptoms of the patients and the like.
The dose of prostaglandin varies depending on the type of prostaglandin. The usual daily dose is within a range of 0.1 to 1,000 μg, which can be administered from once to several times a day. More specifically, latanoprost and isopropyl unoprostone are generally administered at a daily dose of 1 to 5 μg and a daily dose of 30 to 300 μg, respectively. Depending on the age and symptoms of the patients and the like, the doses are varied. Based on similar standards, the doses of the other prostaglandins can be determined.
These doses are also applicable to the administration of the combination of a Rho kinase inhibitor and a prostaglandin. In the case that a Rho kinase inhibitor and a prostaglandin are to be administrated in one formulation, the formulation should be prepared by selecting the mixing ratio of the two drugs appropriately so that their daily doses might not exceed each dose of the separate drugs. The mixed formulation can be administered from once to several times daily.
A formulation example and pharmacological tests are shown in the following Examples. The Examples are for better understanding of the invention, but do not limit the scope of the invention.
A general formulation example of an ophthalmic solution comprising a Rho kinase inhibitor ((R)-(+)-N-(1H-pyrrolo[2,3-b]-pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride) and a prostaglandin (isopropyl unoprostone) in the present invention is shown below.
Ophthalmic solutions having desired combinations and desired concentrations can be prepared by changing the kinds and amounts of the Rho kinase inhibitor and the prostaglandin and by appropriately changing the amounts of the additives.
So as to study the utility of the combination of a Rho kinase inhibitor and a prostaglandin, a Rho kinase inhibitor and a prostaglandin were administered to Japanese white rabbits (strain: JW, sex: male) or cynomolgus monkeys (Macaca fascicularis, sex: male), and the effects on reducing intraocular pressure were examined. (R)-(+)-N-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)-benzamide dihydrochloride [Compound A] or 145-isoquinolinesulfonyl)homopiperazine dihydrochloride [Compound B] was used as the Rho kinase inhibitor. Isopropyl unoprostone or latanoprost was used as the prostaglandin.
The Rho kinase inhibitor was dissolved in physiological saline, and then sodium hydroxide was added to the solution to neutralize it (pH 6.0 to 7.0) to thereby prepare Rho kinase inhibitor solutions having desired concentrations.
A commercially available isopropyl unoprostone ophthalmic solution (trade name: Rescula ophthalmic solution) or a commercially available latanoprost ophthalmic solution (trade name: Xalatan ophthalmic solution) was used as it was, or was diluted with physiological saline to prepare prostaglandin solutions having desired concentrations.
The effect on reducing intraocular pressure by administering the combination of a Rho kinase inhibitor and a prostaglandin was studied. As a reference, the Rho kinase inhibitor was administered singly or the prostaglandin was administered singly, and the effect on reducing intraocular pressure was also studied. As a control, only a vehicle (physiological saline) was administered. As experimental animals, Japanese white rabbits (strain: JW, sex: male) or cynomolgus monkeys (sex: male) were used.
1) One drop of a 0.4% oxybuprocaine hydrochloride ophthalmic solution was instilled into both eyes of each experimental animal to topically anesthetize the eyes.
2) Intraocular pressure was measured immediately before administering the test compound solution, and the intraocular pressure was referred to as initial intraocular pressure.
3) The Rho kinase inhibitor solution was instilled into one eye of each experimental animal (the other eye was not treated). Since it is impossible to instill the prostaglandin solution at the same time, after a short period (about five minutes), the prostaglandin solution was instilled into the same eye.
4) Two, four, six and eight hours after instilling the Rho kinase inhibitor solution, one drop of the 0.4% oxybuprocaine hydrochloride ophthalmic solution was instilled into both eyes to topically anesthetize the eyes. Then the intraocular pressure was measured three times to obtain the average of three measurements.
In Test 2 shown in the following Tests 1-4, intraocular pressure was measured after two, four and six hours.
Each test was carried out in the same manner as in the above-mentioned combination administration test, except that the prostaglandin solution was replaced with physiological saline.
Each test was carried out in the same manner as in the above-mentioned combination administration test, except that the Rho kinase inhibitor solution was replaced with physiological saline.
Each test was carried out in the same manner as in the above-mentioned combination administration test, except that the Rho kinase inhibitor solution and the prostaglandin solution were replaced with physiological saline.
The Rho kinase inhibitor solutions, the prostaglandin solutions and the experimental animals to be used in respective tests are shown in Table 1.
Tests 1 to 4 were carried out according to the above-mentioned method of test, and method of administration and method of measurement.
The results of Test 1, the results of Test 2, the results of Test 3 and the results of Test 4 are shown in
As apparent from
An action of reducing intraocular pressure is increased and/or persistence of the action is improved by administering to the eyes of a patient a Rho kinase inhibitor in combination with a prostaglandin. Accordingly, the combination is useful as a therapeutic agent for glaucoma.
| Number | Date | Country | Kind |
|---|---|---|---|
| JP2002-250223 | Aug 2002 | JP | national |
This application is a continuation application of application Ser. No. 10/525,986 filed Feb. 25, 2005, which is a United States national phase application under 35 USC 371 of International application PCT/JP2003/11004 filed Aug. 29, 2003. The entire contents of each of U.S. Ser. No. 10/525,986 and PCT/JP2003/11004 are hereby incorporated by reference herein.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10525986 | Feb 2005 | US |
| Child | 12589004 | US |
